Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Retained Earnings (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Retained Earnings for 12 consecutive years, with -$42000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings rose 99.99% year-over-year to -$42000.0, compared with a TTM value of -$42000.0 through Sep 2025, up 99.99%, and an annual FY2024 reading of -$548.1 million, down 3.78% over the prior year.
  • Retained Earnings was -$42000.0 for Q3 2025 at Lisata Therapeutics, up from -$50000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at -$42000.0 in Q3 2025 and bottomed at -$552.8 million in Q1 2025.
  • Average Retained Earnings over 3 years is -$341.0 million, with a median of -$522.7 million recorded in 2023.
  • Peak annual rise in Retained Earnings hit 99.99% in 2025, while the deepest fall reached 531428.85% in 2025.
  • Year by year, Retained Earnings stood at -$528.1 million in 2023, then fell by 3.78% to -$548.1 million in 2024, then skyrocketed by 99.99% to -$42000.0 in 2025.
  • Business Quant data shows Retained Earnings for LSTA at -$42000.0 in Q3 2025, -$50000.0 in Q2 2025, and -$552.8 million in Q1 2025.